Hajji

Hajji Acadia announced Q1 2026 net sales of DAYBUE trofinetide of US 101 million up 20 on Q1 2025 the highest year on year

Acadia Pharmaceuticals reported strong 2025 sales for DAYBUE trofinetide and provided 2026 guidance resulting Acadia reports DAYBUE net sales for 2025 and 2026 guidance Neuren Pharmaceuticals Limited ASX NEU 16 46

[img_alt-1]

Hajji
[img-1]

[img_alt-2]

[img_title-2]
[img-2]

[img_alt-3]

[img_title-3]
[img-3]

Trofinetide s clinical trial in Japan is accelerating with results expected September November 2026 indicating Acadia projected that global net sales of DAYBUE trofinetide could reach approximately US 700 million by 2028

First quarter DAYBUE GAAP net sales of 101 million up 20 year over year successful launch of DAYBUE STIX 80 caregiver satisfaction Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for

Download Hajji

Download Hajji

More picture related to Hajji

[img_alt-4]

[img_title-4]
[img-4]

[img_alt-5]

[img_title-5]
[img-5]

[img_alt-6]

[img_title-6]
[img-6]

Outside the US Acadia announced the approval of DAYBUE oral solution by the Ministry of Health in Israel The Phase 3 clinical trial Drug Sales Expectation Change Core Adjustments Net Debt EBITDA Ratios Dividend Yield Revenue High Low Analysis Net Profit

Third quarter DAYBUE trofinetide net product sales of 101 1 million up 11 year over year Continued to [desc-11]

[img_alt-7]

[img_title-7]
[img-7]

[img_alt-8]

[img_title-8]
[img-8]

Q1 2026 DAYBUE 174 Net Sales US 101m Up 20 From Q1 2025

https://company-announcements.afr.com › asx › neu
Acadia announced Q1 2026 net sales of DAYBUE trofinetide of US 101 million up 20 on Q1 2025 the highest year on year

Get More Here!!